MOPA — Medical Oncology Prior Authorization
0.1.1-snapshot-080926 - snapshot-080926 United States of America flag

MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

CodeSystem: Treatment Line Code System (Experimental)

Official URL: http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs Version: 0.1.1-snapshot-080926
Standards status: Informative Computable Name: TreatmentLineCS

Ordinal codes representing the line of systemic anti-cancer therapy. These codes are used in TreatmentLineVS and in the LineOfTherapyRequestCategory constraint profile for the RequestGroup lineOfTherapy category slice.

mCODE Migration Candidate — These codes are proposed for adoption in mCODE STU5 or as a SNOMED CT extension request. Once standard codes are available, this code system should be deprecated.

⚠ mCODE Migration Candidate

This Treatment Line Code System is defined in this IG as a temporary home while a formal proposal to incorporate it into mCODE STU5 is developed. It is not intended to be a permanent artifact of the MOPA IG. Once adopted by mCODE, this IG will remove its local definition and reference the mCODE canonical URL instead.

This artifact carries status = draft and experimental = true. Canonical URLs will change at migration. See the mCODE Gap Proposals page for the full proposal backlog.

This Code system is referenced in the definition of the following value sets:

This case-sensitive code system http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs defines the following codes:

CodeDisplayDefinition
1L First-line The first line of systemic anti-cancer therapy for this indication.
2L Second-line The second line of systemic anti-cancer therapy; administered after first-line therapy failure, progression, or intolerance.
3L-plus Third-line or later The third or any subsequent line of systemic anti-cancer therapy.
maintenance Maintenance Maintenance therapy administered to prolong response after induction or consolidation treatment.

Description of the above table(s).